Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.10
EPS est.
$-0.29
EPS surprise
+65.99%
1-day move
-1.41%
10x Genomics reported a larger-than-expected loss per share but did not provide revenue figures. The stock reacted negatively, declining by 1.41%. Investors may be concerned about the lack of revenue clarity and guidance moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.10 | $-0.06 | +65.99% |
| Revenue | — | $147M | — |
No transcript is on record, and the analysis is based on numerical results only.
10x Genomics, Inc. is a health care company that specializes in life sciences tools and services, primarily focusing on genomic technologies. Their innovative products enable researchers to analyze biological systems at a deeper level, which is crucial for advancements in personalized medicine and disease research.
Last quarter
In the last quarter, 10x Genomics reported an EPS of -$0.13, which was better than the expected -$0.19, leading to a positive surprise. However, the stock fell by 8.56% the following day, indicating market concerns despite the beat.
EPS beat streak
6Q
EPS beat rate
88%
Avg EPS surprise
+44.72%
Avg 1-day reaction
-1.44%
Analysts are cautiously optimistic, expecting a slight improvement in EPS and revenue compared to previous quarters. However, the company's history of mixed results may temper enthusiasm.
Bull case
If 10x Genomics can show stronger-than-expected revenue growth and improved margins, it could signal a turnaround in demand for its products, boosting investor confidence.
Bear case
Conversely, if the company fails to meet revenue expectations or shows continued losses, it could lead to further declines in stock price and investor sentiment.
Key metrics to watch
EPS
-$0.06Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$147MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the revenue exceed the consensus estimate of $147M?
Revenue growth is critical for assessing demand for 10x Genomics' products and overall business health.
Q2
How will management address the ongoing losses indicated by the expected EPS of -$0.06?
Investors will be keen to understand the company's path to profitability and any strategic changes that may be implemented.
—
Est. EPS
$0.97
Est. Rev
$754M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for revenue growth driven by new product launches and increased market adoption.
Supporting evidence
The company has a history of surprising on the upside, with a 75% EPS beat rate.
Options pricing suggests a significant move, indicating that traders expect volatility and potential positive news.
Recent insider selling may reflect confidence in the company's long-term strategy despite short-term losses.
Key risk
If revenue exceeds $150M, it could shift the narrative towards growth and recovery.
Pre-commit to what would confirm each case.
The market is debating whether 10x Genomics can turn its recent performance around and achieve sustainable growth.
Bull confirmed if
Revenue growth exceeding $150M would confirm a positive outlook and strong demand.
Bear confirmed if
An EPS worse than -$0.09 would reinforce concerns about the company's financial stability.
What the market is pricing for the move.
Implied Move
±23.6%
Historical Avg
±3.1%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.
Options are pricing ±23.6% while TXG has averaged ±3.1% over the last 8 prints — setup is pricing rich.
ATM IV
1.7%
30d HV
63.2%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: X of Y (Z%)
This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 5.9%, with a raw directional average of -0.5% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
120.32%
of float
Insider
1.44%
of float
Holders
524
institutions
Top Holders· as of Jun 2026
FMR, LLC
17,629,266 sh · $1.3B
14.67%
-0.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If 10x Genomics beats expectations, history suggests the stock could rise by around 0.03% on average, confirming a positive trend.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
Should the company miss estimates, history suggests a potential decline of about 2.31%, reflecting ongoing investor concerns.
The lines on the call that would change the story.
Blackrock Inc.
10,804,070 sh · $822.2M
8.99%
7.2%
ARK Investment Management, LLC
10,003,057 sh · $761.2M
8.32%
-14.6%
Vanguard Portfolio Management LLC
6,982,492 sh · $531.4M
5.81%
1.0%
Quantinno Capital Management, LP
5,469,698 sh · $416.2M
4.55%
1.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.